Dr. Jeanmarie Guenot’s Efforts to Eradicate Deadly Diseases by Developing Innovative Drugs

Jeanmarie Guenot boasts more than two decades of experience in the arena of biotechnology and pharmaceutical. She has the privilege of working with firms of all stages, ranging from pharmaceutical R&D, business development, corporate & commercial development, and venture capital. Guenot has unsurpassed expertise and talent in creating and recreating companies. Today, she is the head of Amphivena Therapeutics, Inc., a prominent firm that is creating unique bifunctional antibody medicines for the management of hematologic malignancies. In 2013, Amphivena Therapeutics conducted a Series A funding headed by MPM Capital and managed to raise a record $14 million.

 

Contributions to the expansion of pharmaceutical sector

 

Jeanmarie Guenot launched her professional business career at the renowned Atlas Venture, where she oversaw venture capital investments and established life science firms. She commenced her career as a researcher and scientist after joining the Hoffmann-La Roche’s Preclinical R&D as the principal scientist. Guenot led a team of researchers in discovering and creating medications for autoimmune diseases, metabolic diseases, oncology, and inflammation.

 

Jeanmarie Guenot offered business advisory services to Hoffmann-La Roche in Shanghai and Basel. At a particular time in her career, Guenot was the VP of PDL Alliance Management in charge of managing commercial product portfolios. She oversaw and led the negotiations of the Biogen Idec-PDL 50:50 co-design and co-commercialization partnership that comprised of three Phase 2 drugs for the treatment of autoimmune and cancer. Guenot has a diversified portfolio consisting of extensive experience in project and partnership management, especially in the specialties of cardiovascular diseases, neurology, oncology, ophthalmic disease.

 

Innovation

 

Guenot is a creative individual behind several well-performing medications and state-of-the-art equipment. She incepted, developed, and operated SKS Ocular, an innovative ophthalmic company incubator that concentrates on dry AMS, macular degeneration, reliable ocular drug delivery techniques, and ocular inflammation.

Follow along with the rest of her career here: http://jeanmarieguenot.com/

 

Education

 

Guenot is a trained scientist in the fields of medicinal and physical chemistry. She has specialized in semi-empirical as well as quantum mechanical techniques for protein structure prediction, drug development, molecular dynamics, and refinement of NMR and X-ray. Guenot studied at the University of California and obtained her Ph.D. She attained her MBA from the celebrated University of Pennsylvania’s The Wharton School.